Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22734104 | 0.97 | KMT2A (0.40) | KMT2APDE4AADORA3ADORA1ADORA2A | |
| SCHEMBL22734105 | 0.96 | KMT2A (0.43) | KMT2APDE4AADORA3ADORA1ADORA2A | |
| SCHEMBL15976749 | 0.94 | KMT2A (0.33) | KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL31474619 | 0.88 | ADORA3 (0.32) | KMT2AADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20840622 | 0.88 | MAPK1 (0.35) | KMT2AADORA3 | |
| SCHEMBL516176 | 0.88 | MAPK1 (0.35) | KMT2AADORA3 | |
| SCHEMBL20851935 | 0.88 | MAPK1 (0.35) | KMT2AADORA3 | |
| SCHEMBL30785572 | 0.85 | GLP1R (0.32) | — | |
| SCHEMBL22734110 | 0.84 | — | — | |
| SCHEMBL31491372 | 0.84 | CHRM3 (0.33) | KMT2APDE4AADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724195-B1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| US-11299497-B2 | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-04-12 | — | — | US | disclosed |
| US-20200385400-A1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299497-B2 | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE5A, PDE4A, PDE7A | KMT2A 2875/4885PDE4A 2/4885ADORA3 1539/4885 |
| US-20200385400-A1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE5A, PDE4A, PDE7A | KMT2A 2875/4885PDE4A 2/4885ADORA3 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.